At a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors that are hard to treat. Kancera has already reported...
Read MoreiNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development...
Read MoreThe Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011. Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer...
Read MoreIn line with Kancera's strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of...
Read MoreROR-1, target for the Kancera treatment for chronic lymphatic leukemia, has been identified on the surface of eight additional blood cancers. Accordingly, medical use of the Kancera candidate drug under development may be expanded within the frames of current...
Read MoreKancera AB (publ) announces that the acquisition of iNovacia AB has been implemented
Read MoreAs of 2 February 2011, Kancera AB’s future subsidiary iNovacia AB has sold its entire holding of 864,000 shares in Kancera AB at the price of SEK 7 per share. This means that the Kancera Group will receive around...
Read MoreKancera AB has in collaboration with Sprint Bioscience AB, Stockholm, solved the 3- dimensional crystal structure of a novel chemical class in complex with the target enzyme PFKFB3, by conducting experiments at the European Synchrotron Radiation Facility in Grenoble....
Read MoreKancera AB has discovered compounds that kill Chronic Lymphocytic Leukemia (CLL) 25 times more selectively than cytostatic drugs currently used for treating the disease.
Read MoreKancera AB (publ) is carrying out a new share issue, will be listed on First North, and is acquiring the research company iNovacia AB - thereby creating an international and highly competitive cancer drug company.
Read More